VIVES is a multi-sector fund that invests in projects with a positive societal impact
3D-Side assists surgeons by integrating 3D technologies into the operating room. They combine the precision of engineering with medical expertise to individualize the surgical treatment of each...
BiocSol develops next-generation biopesticides through their proprietary platform, harnessing well-defined natural compounds produced by beneficial microorganisms.
Their journey began with a clear...
Since 1957, humanity has been launching objects into space, but most were designed to be static, rigid and non-servicable, remaining in orbit for decades without the ability to move, adapt, or be...
David Frenay, CEO Emolytics:
"Emolytics is a spin-off of the UCLouvain, founded in 2014 and acquired by Profacts in 2018. Emolytics has been supported by VIVES II Fund since its inception, as VIVES...
Pierre Delatte, CTO and co-founder of Cissoid:
"With the VIVES fund, we have found a partner who understands the challenge of bringing technology from a university laboratory to the commercialization...
Issam Doghri, Prof. at UCLouvain and co-founder of e-Xstream engineering:
"I developed a first version of a software (Digimat- for digital materials) and I was thinking about ways to make it...
Trial aims to enroll 12 children at eight sites in EU and US
Phase 3 trial in adult patients also planned for 2026 with focus on limb sparing associated with bone non-union (BNU)
Novadip aims to
Proceeds will advance clinical development of Nuclidium’s true theranostic pipeline and expand its global production and manufacturing network for copper-based radiopharmaceuticals
Participation is